FDA Pharmacoepidemiology Office Adds Jonca Bull
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.
ODE V director joins effective May 2 as deputy director, leaving only one major vacancy in OPaSS. Reorganization of the Office of New Drugs is eliminating ODE V.